Ultimately, the research showed that immune cells need physical as well as chemical cues to properly manage PD-1 activity, ...

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

PD-L1 is a widely used biomarker for cancer patient selection for checkpoint inhibitors, a class of cancer drugs representing ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic ...

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting ...

Additionally, their oral PD-L1 inhibitor, AB-101, demonstrated safety and receptor occupancy in early trials, positioning the company well for future clinical developments. For further insights into ...

Roche’s market capitalisation growth of 13.8% was driven by FDA approvals for two key products in September 2024: Ocrevus ...